WO2019146394A1 - 薬剤供給装置 - Google Patents

薬剤供給装置 Download PDF

Info

Publication number
WO2019146394A1
WO2019146394A1 PCT/JP2019/000157 JP2019000157W WO2019146394A1 WO 2019146394 A1 WO2019146394 A1 WO 2019146394A1 JP 2019000157 W JP2019000157 W JP 2019000157W WO 2019146394 A1 WO2019146394 A1 WO 2019146394A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
treated
water
permeable membrane
medicine
Prior art date
Application number
PCT/JP2019/000157
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
廣田　達哉
真二郎 野間
ゆうこ 丸尾
藤田　浩史
太輔 五百崎
Original Assignee
パナソニックＩｐマネジメント株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パナソニックＩｐマネジメント株式会社 filed Critical パナソニックＩｐマネジメント株式会社
Priority to JP2019567955A priority Critical patent/JPWO2019146394A1/ja
Priority to CN201980009943.1A priority patent/CN111655627A/zh
Publication of WO2019146394A1 publication Critical patent/WO2019146394A1/ja

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F21/00—Dissolving
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/44—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Definitions

  • the present disclosure relates to a drug supply device for supplying a drug to treated water.
  • the dispersing agent may, for example, be one in which a solid drug is supported by the drug support or a liquid drug is supported by a permeable membrane.
  • the drug support or permeable membrane is provided with a large number of pores. Therefore, the water to be treated which has passed through the many holes from the bottom comes in contact with the drug. Thereby, the drug dissolves in the water to be treated (see Patent Document 1).
  • solid or liquid drug is simply placed on the drug support or permeable membrane. Therefore, the concentration of the drug contained in the water to be treated may vary due to the fluctuation of the flow rate of the water to be treated.
  • the present disclosure has been made in view of the problems of the related art. And the objective of this indication is to provide the chemical
  • a medicine supply device concerning one mode of this indication is provided inside a container part which can open an upper end, and the container part, and it extends upward from a bottom part and the bottom part, and A drug bath including a peripheral wall portion surrounding a space above the bottom surface portion and having at least one communication hole in at least one of the bottom surface portion and the peripheral wall portion; and connected to the bottom surface portion from below the bottom surface portion
  • the pore diameter of the permeable membrane does not allow the drug supported by the permeable membrane to permeate before the treated water permeates the permeable membrane and contacts the drug, but the treated water Is a size that allows permeation of the drug contained in the water to be treated after having permeated through the permeable membrane and brought into contact with the drug, and the dispersed gap of the dispersion material is the drug It is in the state which allows the to-be-treated water containing to flow to the at least one communicating hole.
  • the drug supply device 100 according to the embodiment will be described below with reference to FIGS. 1 to 3.
  • the medicine supply device 100 of the embodiment includes the container portion 12.
  • the container 12 includes a container body 2 whose upper end is opened, and a lid 1 removably attached to the container body 2 so as to close the opening at the upper end of the container body 2. .
  • the container body 2 has a cylindrical peripheral wall and a disk-like bottom.
  • the lid portion 1 has a disk-like upper surface portion, and an annular peripheral wall portion hanging down from the circumferential portion of the upper surface portion, which is slightly larger than the cylindrical peripheral wall portion of the container body 2.
  • the container part 12 may have any shape as long as it can form a space inside.
  • the drug supply device 100 is provided inside the drug tank 21 and includes a drug storage unit 40 containing a drug CA. Therefore, according to the present embodiment, only by removing the lid 1 from the container main body 2, without directly touching the drug CA with the drug CA in a state in which the drug container 40 is held by hand, It can be put into 21. As a result, it is possible to suppress adverse effects on the hands of the worker when the drug CA is introduced into the drug supply device 100.
  • the medicine containing portion 40 includes the medicine CA by the permeable membrane 42, the cylindrical side wall 41, and the upper end closing portion 43 described later.
  • the drug tank 21 includes a disc-like bottom surface 21Y and a cylindrical peripheral wall 21X extending upward from the outer peripheral end of the bottom 21Y and surrounding a space above the bottom 21Y.
  • the bottom portion 21Y of the medicine tank 21 may have any shape such as a square plate or the like as long as the dispersion material F described later can be placed thereon.
  • the peripheral wall portion 21X may have any shape such as a rectangular cylindrical shape.
  • the medicine tank 21 is a continuous integrated body that can not distinguish between the peripheral wall portion 21X and the bottom surface portion 21Y, such as a shape of a partially cut spherical shell, a shape of wine glass, or a shape of a bathtub. It may be a structure.
  • the medicine tank 21 may include a bottom 21Y having a concave lens shape and a peripheral wall 21X having a cylindrical curved surface portion continuous with an end of the concave lens shape.
  • the medicine tank 21 has at least one communication hole 21A in the bottom surface 21Y, which penetrates the bottom surface 21Y in the thickness direction.
  • at least one communication hole 21A is provided in the bottom portion 21Y.
  • at least one communication hole 21A may be provided on the lower side of the peripheral wall 21X as long as it is covered by the dispersion material F described later.
  • the number of at least one communication hole 21A is eight (see FIG. 2) in the present embodiment, but may be any number.
  • a dispersion material F having a thickness t is provided inside the medicine tank 21, a dispersion material F having a thickness t is provided.
  • the dispersion material F has a dispersed gap.
  • Dispersing material F is gravel in the present embodiment.
  • the thickness t of the dispersing agent F can be changed by changing the amount of gravel.
  • PAC polyaluminum chloride
  • the dispersion material F supports the medicine container 40.
  • the dispersion material F disperses the to-be-treated water W introduced in a concentrated manner in one place in the medicine tank 21 by letting the dispersion material F pass through each of the gaps dispersed in the to-be-treated water W.
  • the dispersion material F also has an effect of rectifying the water to be treated W in the medicine tank 21.
  • the dispersion material F is placed on the bottom surface 21Y inside the peripheral wall 21X so as to cover each of the at least one communication hole 21A.
  • the medicine tank 21 has an internal space whose upper side is opened inside the peripheral wall 21X so that the medicine container 40 can be put on the dispersion material F. Therefore, only by removing the lid 1 from the container body 2, the medicine container 40 can be easily introduced from the outside of the container body 2 into the internal space above the dispersion material F.
  • the dispersion material F supports the drug storage unit 40 when it is introduced into the internal space, but the water W to be treated comes into contact with the drug CA in the drug storage unit 40, and the treatment to which the drug CA is dissolved It allows the water W to flow to the at least one communication hole 21A.
  • a communication space 11B is formed at an upper side and a side of the medicine tank 21 in the container portion 12.
  • the communication space 11B brings the space in the medicine tank 21 into communication with the lead-out flow path 11C. Therefore, air can freely move between the space in the medicine tank 21 and the outlet channel 11C via the communication space 11B. Therefore, the air inside the container 12 is prevented from flowing out of the container 12 together with the water W to be treated.
  • Dispersing material F in the present embodiment is a gravel made of a group of particles, so dispersing material F can be easily obtained using existing materials.
  • the drug CA when the drug CA is dissolved in the water to be treated W, it is a solid chlorine drug that exhibits acidity. Therefore, for the purpose of neutralization, as the dispersing agent F, it is preferable to use a member that exhibits alkalinity when dissolved in the water to be treated W.
  • the member that exhibits alkalinity when dissolved in the water to be treated W includes, for example, at least one of a group of readily available existing cement pieces, a group of coral stones, and a group of limestones. According to this, by adjusting the amount of the dispersing material F, the to-be-treated water W that has become acidic can be brought closer to neutrality.
  • the dispersing material F has a dispersed gap, and by dispersing the water to be treated W, the water to be treated W can be brought into contact with almost the entire lower surface of the medicine CA in the medicine container 40 uniformly. If there is, it may be anything.
  • the dispersion material F may be, for example, a laminated structure of a plurality of non-woven fabrics or a laminated structure of a plurality of woven fabrics.
  • the dispersion material F may be, for example, a group of deposited granular members, a three-dimensional fibrous structure in which fibers are intertwined, or a porous member having a structure similar to a sponge.
  • Dispersing material F is a natural material such as a group of filter media or a group of sand grit including a group of sand particles or a group of stone particles, provided that the treated water W can be dispersed by having the dispersed gaps. It may be In addition, the individual members constituting the dispersion material F may be man-made materials such as metal, plastic, resin, or fiber. That is, the dispersion material F has a dispersed gap, can support the drug storage unit 40, and disperses the water to be treated W, so that substantially the entire lower portion of the drug CA in the drug storage unit 40 can be dispersed. Any material may be used as long as it can be brought into contact with the water W to be treated.
  • the drug CA is uniformly dissolved in the water to be treated W by uniformly contacting the dispersed water to be treated W with the whole of the lower surface of the drug CA in the drug containing portion 40. Can. As a result, it becomes easy to keep the dissolved concentration of the drug CA in the water to be treated W almost constant.
  • the dispersed space of the dispersion material F is in a state where it allows the treated water W in which the drug CA is dissolved to flow to at least one communication hole 21A.
  • the permeable membrane 42 is provided on the inner side of the drug tank 21 and on the upper side of the dispersion material F so as to support the drug CA, and allows the water to be treated W dispersed by the dispersion material F to permeate.
  • the pore diameter of the permeable membrane 42 is such a size that the agent CA supported by the permeable membrane 42 does not permeate before the water to be treated W permeates the permeable membrane 42 and contacts the agent CA. Further, the pore diameter of the permeable membrane 42 is such that the substance constituting the drug CA dissolved in the treated water W can permeate after the treated water W permeates the permeable membrane 42 and contacts the drug CA. It is a size.
  • the to-be-treated water W permeates the permeable membrane 42 and comes into contact with the drug CA
  • the to-be-treated water W containing the drug CA passes through the permeable membrane 42 It is gradually released to the dispersing agent F side. Therefore, not only the function of the dispersion material F but also the function of the permeable membrane 42 can suppress the variation in the concentration of the drug CA in the water to be treated W.
  • the pore size of the permeable membrane 42 is such a size as to allow atoms, molecules or ions of the substance constituting the drug CA dissolved in the water to be treated W to permeate.
  • the pore diameter of the permeable membrane 42 is more preferably 0.01 ⁇ m to 10 ⁇ m from the viewpoint of setting the concentration of the drug CA to the water to be treated W to an appropriate value.
  • medical agent CA is appropriately sustained-released to the to-be-processed water W can be easily formed using the material marketed. .
  • the pore size of the permeable membrane 42 depends on the viscosity of the drug CA. More specifically, the pore size of the permeable membrane 42 depends on the concentration of the drug CA and the molecular weight of the substance constituting the drug CA. If the viscosity of the drug CA is high, the pore diameter of the permeable membrane 42 may preferably be larger than 10 ⁇ m because the surface tension of the drug CA is high. If the viscosity of the drug CA is low, the pore diameter of the permeable membrane 42 may preferably be smaller than 0.01 ⁇ m because the surface tension of the drug CA is low. Considering such matters, the following may be considered as the permeable membrane 42, for example.
  • the permeable film 42 at least one of an organic film made of a polymer and an inorganic film made of an inorganic material represented by ceramics may be used.
  • membrane Micro-Filtration Membrane
  • membrane Ultra-Filtration Membrane
  • membrane Ultra-Filtration Membrane
  • the pore size of the MF membrane is about 0.01 ⁇ m to 10 ⁇ m.
  • the pore size of the UF membrane is about 0.001 ⁇ m to 0.01 ⁇ m.
  • a PSF (polysulfone) membrane, a PE (polyethylene) membrane, a CA (cellulose acetate) membrane, a PAN (polyacrylonitrile) membrane or the like may be used.
  • a PP polypropylene
  • PVDF polyvinylidene fluoride
  • a PTFE polytetrafluoroethylene
  • an NF film (Nano-Filtration Membrane) or an RO film (Reverse Osmosis Membrane) may be used as an organic film constituting the permeable film 42.
  • the pore diameter of the NF film is about 1 nm to 2 nm.
  • the pore size of the RO membrane is about 2 nm or less.
  • a polyamide-based organic membrane may be used as the NF membrane or RO membrane constituting the permeable membrane 42.
  • an MF membrane, a UF membrane, or an NF membrane using a metal membrane or a ceramic may be used as the inorganic membrane constituting the permeable membrane 42.
  • the permeable membrane 42 does not permeate the drug CA supported by the permeable membrane 42 before the treated water W permeates the permeable membrane 42 and contacts the drug CA, but the permeable membrane 42 is included in the treated water W. Any agent may be used as long as it allows the agent CA to permeate.
  • the dispersion material F is introduced from the opening at the upper end of the medicine tank 21 onto the bottom surface portion 21 ⁇ / b> Y.
  • Dispersing material F is drawn as a single mass for the sake of convenience in FIG. 2, but in practice it is composed of a large number of grains in which individual grains can be dispersed.
  • the peripheral wall portion 21X of the medicine tank 21 is a cylinder as described above.
  • the bottom surface portion 21Y of the medicine tank 21 is a disk through which the virtual central axis of the cylinder formed by the peripheral wall portion 21X passes the virtual central point. Therefore, in the present embodiment, eight communication holes 21A are provided on the bottom surface 21Y along the circumference of the disk-shaped bottom surface 21Y at circumferential angles of 45 degrees.
  • the eight communication holes 21A are an example of the plurality of communication holes 21A. That is, the plurality of communication holes 21A are provided along the circumference of the disc at equal angular intervals at the same circumferential angle. Therefore, the water to be treated W can be brought into contact with the entire lower surface of the medicine CA as uniformly as possible.
  • the number of the communication holes 21A is the same as that of the bottom surface portion at the same circumferential angle, such as two, three, four, five, six, nine, ten, or twelve. Any number may be provided as long as it is provided along the circumference of the disc constituting 21Y. Moreover, it is preferable that each of the plurality of communication holes 21A have the same shape. Each of the plurality of communication holes 21A has the same circular cross section in the present embodiment. However, even if each of the plurality of communication holes 21A is an elongated hole extending along the radial direction of the circular bottom portion 21Y, or an arc-shaped hole extending along the circumferential direction of the circular bottom portion 21Y, etc. Good.
  • a mesh member 30 is provided between the dispersion material F and the bottom portion 21 ⁇ / b> Y.
  • the mesh member 30 has a group of openings whose size is smaller than at least one communication hole 21A.
  • the mesh member 30 is provided to cover all of the at least one communication hole 21A.
  • the mesh member 30 suppresses the passage of each particle constituting the dispersion material F, but has a size that allows the water to be treated W to pass.
  • the dispersion material F is a group of granular members such as gravel. Therefore, the mesh member 30 can suppress the flow of the particulate material of a part of the dispersion material F from the at least one communication hole 21A. However, if the size of the communication hole 21A is smaller than the size of one particle constituting the dispersion material F, that is, if one particle constituting the dispersion material F can not pass through the communication hole 21A, the mesh member 30 is It does not have to be provided.
  • the container unit 12, the drug tank 21, and the drug storage unit 40 are formed of a transparent material. Therefore, the remaining amount of the drug CA can be easily grasped from the outside of the container unit 12.
  • the introduction channel 11A is connected to the bottom surface 21Y from below the bottom surface 21Y.
  • the introduction channel 11A is a cylindrical space inside the cylindrical channel 11 connected to the lower surface of the bottom surface 21Y.
  • the introduction flow path 11A guides the water to be treated W from the outside of the container unit 12 to the inside of the medicine tank 21.
  • the inlet channel 11A is connected to the circular opening of the bottom surface 21Y so that the virtual central axis of the cylindrical inlet channel 11A passes the position of the virtual center of the disc constituting the bottom surface 21Y.
  • the water to be treated W flowing through the introduction channel 11A flows into the medicine tank 21.
  • the water to be treated W enters the dispersed gap between the particles constituting the dispersion material F and is dispersed. Thereby, the water to be treated W permeates the permeable membrane 42 and contacts the entire lower surface of the drug CA almost uniformly.
  • medical agent supply apparatus 100 is positioned below the lower surface of the bottom face part 21Y. Therefore, when the drug supply device 100 is not in use, the drug CA does not dissolve in the water to be treated W. That is, the release of the drug CA passing through the permeable membrane 42 to the dispersion material F side is stopped. Therefore, due to dissolution of drug CA in treated water W when drug supply apparatus 100 is not used, the dissolved concentration of drug CA in treated water W temporarily at the beginning of the start of use of drug supply apparatus 100 Unevenness is prevented.
  • the to-be-treated water W in contact with the drug CA passes through the at least one communication hole 21A and falls into the lower outlet flow passage 11C of the at least one communication hole 21A.
  • the lead-out flow passage 11C is a space inside the container body 2 and a space outside the conduit 11.
  • the outlet channel 11C guides the water to be treated W, which has fallen from the inside of the drug tank 21 via the at least one communication hole 21A, to the outside of the container portion 12.
  • the drug storage unit 40 has a tubular side wall 41 and a permeable membrane attached to the tubular side wall 41 so as to cover the lower opening of the tubular side wall 41. And 42.
  • the permeable film 42 covering the lower opening of the cylindrical side wall 41 is attached to the lower end surface of the cylindrical side wall 41.
  • the permeable membrane 42 covering the lower opening of the cylindrical side wall 41 is attached to the inner circumferential surface of the cylindrical side wall 41 at a position somewhat above the lower end of the cylindrical side wall 41 It is also good. That is, as long as the permeable membrane 42 is attached to the cylindrical side wall 41 so as to constitute the bottom of the medicine container 40, any material may be used.
  • the permeable membrane 42 is insert-molded in the cylindrical side wall portion 41 in the present embodiment. Therefore, a process such as adhesion of the permeable membrane 42 is unnecessary, and it can be formed at a very low cost.
  • the permeable membrane 42 may be attached to the cylindrical side wall 41 by any other means such as an adhesive.
  • the drug CA is introduced inside the cylindrical side wall 41 and on the permeable membrane 42.
  • the cylindrical side wall portion 41 has a cylindrical shape in the present embodiment, but as long as it has a wall having an inner peripheral surface, it may have any shape such as a rectangular cylindrical shape. .
  • the permeable membrane 42 is provided so as to constitute the bottom of the medicine containing portion 40, but any inner side of the medicine tank 21 and the upper side of the dispersion material F may be used. It may be provided at a position. For example, it may be attached to the inner peripheral surface of the medicine tank 21.
  • cylindrical peripheral wall portion 21X of the medicine tank 21 may be divided into two at the top and the bottom, and may be sandwiched between the circular end surfaces of the two cylindrical peripheral wall portions 21X.
  • the two cylindrical peripheral walls 21X are further fitted into other cylindrical members and fixed to each other.
  • the thickness of the dispersion material F can be easily changed by taking out the medicine storage unit 40 from the medicine tank 21 with the lid 1 removed from the container body 2. be able to. Therefore, the concentration of the drug CA can be easily adjusted. Further, cleaning or replacement of the dispersion material F and cleaning of the inner surface of the medicine tank 21 can be easily performed.
  • the medicine accommodating portion 40 is provided at the cylindrical side wall portion 41 so as to close the opening at the upper end of the cylindrical side wall portion 41 in a manner capable of opening the upper end opening of the cylindrical side wall portion 41.
  • Part 43 is included. Therefore, it is possible to suppress the leakage of the drug CA from the opening on the upper side of the cylindrical side wall portion 41 when the drug storage portion 40 is transported. Further, if the upper end closing portion 43 is removed from the cylindrical side wall portion 41, replenishment of the drug CA into the drug containing portion 40 can be easily performed.
  • the degree of sealing between the upper end closing portion 43 and the cylindrical side wall portion 41 is irrelevant to the sustained release of the drug CA, so that the drug CA does not leak from the drug storage unit 40 when the drug CA is replenished. Good.
  • the medicine containing portion 40 has the upper end closing portion 43 as a lid independent of the cylindrical side wall 41, and the state where the lid is removed from the cylindrical side wall 41. Then, the drug CA is introduced from above into the inside of the cylindrical side wall portion 41.
  • the medicine container 40 if the medicine CA can be introduced from the upper side into the space inside the cylindrical side wall 41, the upper end closing part 43 and the cylindrical side wall 41 are integrated, The upper end closing portion 43 may function as an open / close door on the cylindrical side wall portion 41.
  • the medicine container 40 may have any structure as long as it has a structure capable of opening the upper end.
  • the structure of the upper end closing portion 43 may be a sliding door structure or an open door structure.
  • the upper end closing portion 43 may be attached to a certain extent downward from the upper end of the cylindrical side wall portion 41 as long as the opening of the upper end of the cylindrical side wall portion 41 can be opened.
  • the drug CA may be either a solid drug or a liquid drug.
  • the drug CA is a solid chlorine drug, for example, chlorinated isocyanuric acid may be used.
  • the drug CA is a chlorine-based drug that exhibits acidity when dissolved in the water to be treated W.
  • the drug CA may be either a granular drug that does not have a fixed shape and a tablet that has been solidified into a certain shape.
  • the drug CA may be a viscous material that can be deformed by flowing.
  • examples of components of the drug CA of granular, solid, liquid or viscous material include a sulfuric acid band, ferric chloride, ferric polysulfate, or lime. Etc. may be used. These exert an effect as a coagulant.
  • the drug CA is supported by the permeable membrane 42 before the to-be-treated water W permeates the permeable membrane 42 and comes in contact with the drug CA, and after the to-be-treated water W permeates the permeable membrane 42 As long as it permeate
  • the hardness and material properties of the drug CA may be any.
  • the lid portion 1 independent of the container body portion 2 is provided, and in the state where the lid portion 1 is removed from the container body portion 2, inside the medicine tank 21 in the medicine supply device 100, The drug storage unit 40 containing the drug CA is charged from above.
  • the medicine container 40 can be inserted into the space inside the medicine tank 21 from the upper side, the container 12 is integrated with the lid 1 and the container body 2, and the container 12 is opened and closed in the lid 1. It may have a door of the formula.
  • the medicine container 40 passes through the door from above the lid 1 and the medicine container 40 is inserted inside the medicine tank 21. That is, as long as the container part 12 has a structure which can open an upper end, ie, a structure by which the opening of an upper end is opened and closed, it may be anything.
  • the drug supply device 100 includes the container unit 12, the drug tank 21, the introduction flow channel 11A, the discharge flow channel 11C, the dispersion material F, and the permeable membrane 42.
  • the container 12 is openable at its upper end.
  • the drug reservoir 21 is provided inside the container portion 12 and includes a bottom surface 21Y and a peripheral wall 21X extending upward from the bottom surface 21Y and surrounding a space above the bottom surface 21Y.
  • the drug tank 21 has at least one communication hole 21A in at least one of the bottom surface 21Y and the peripheral wall 21X.
  • the introduction channel 11A is connected to the bottom surface 21Y from below the bottom surface 21Y, and guides the water to be treated W from the outside of the container 12 to the inside of the medicine tank 21.
  • the outlet channel 11C guides the water to be treated W, which has fallen from the inside of the drug tank 21 via the at least one communication hole 21A, to the outside of the container portion 12.
  • the dispersion material F is placed on the bottom surface 21Y inside the peripheral wall 21X so as to cover at least one communication hole 21A, has a dispersed gap, and the water W to be treated W inside the medicine tank 21 Distribute
  • the permeable membrane 42 is provided on the inner side of the drug tank 21 and on the upper side of the dispersion material F so as to support the drug CA, and allows the water to be treated W dispersed by the dispersion material F to permeate.
  • the pore diameter of the permeable membrane 42 is such a size that the agent CA supported by the permeable membrane 42 does not permeate before the water to be treated W permeates the permeable membrane 42 and contacts the agent CA. Further, the pore diameter of the permeable membrane 42 is such a size as to allow the drug CA contained in the treated water W to permeate after the treated water W permeates the permeable membrane 42 and contacts the drug CA. .
  • the dispersed space of the dispersion material F is in a state where it allows the water to be treated W containing the drug CA to flow to the at least one communication hole 21A.
  • the water to be treated W dispersed by the dispersion material F permeates the permeable membrane 42 and contacts the drug CA, so that the drug CA can be gradually released to the water to be treated W.
  • the flow rate of the water to be treated W fluctuates, it is possible to suppress the variation in the concentration of the drug CA dissolved in the water to be treated W.
  • Dispersing material F is at least one of a group of gravels, a group of gravels, a laminated woven fabric, a laminated non-woven fabric, a filter medium, a group of granular members, a three-dimensional fiber structure, and a porous member You may include one. According to this, the dispersive material F can be easily formed using the existing material.
  • the pore size of the permeable membrane 42 may be 0.01 ⁇ m to 10 ⁇ m. According to this, it is possible to adjust the concentration of the drug CA to the water to be treated W to an appropriate value.
  • the drug supply device 100 may include the drug storage unit 40 provided inside the drug tank 21.
  • the medicine container 40 may include a cylindrical side wall 41 and a permeable membrane 42.
  • the permeable membrane 42 may be attached to the cylindrical side wall 41 so as to constitute the bottom of the medicine container 40.
  • the drug CA is introduced inside the cylindrical side wall portion 41 and on the permeable membrane 42.
  • the thickness of the dispersing agent F can be easily changed. Therefore, the concentration of the drug CA can be easily adjusted.
  • the medicine containing portion 40 includes the upper end closing portion 43 provided on the cylindrical side wall portion 41 so as to close the opening of the upper end in a manner capable of opening the opening of the upper end of the cylindrical side wall portion 41 It may be According to this, it is possible to suppress the drug CA from flowing out from the opening of the upper end of the cylindrical side wall portion 41.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hydrology & Water Resources (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental & Geological Engineering (AREA)
  • Water Supply & Treatment (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
PCT/JP2019/000157 2018-01-24 2019-01-08 薬剤供給装置 WO2019146394A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019567955A JPWO2019146394A1 (ja) 2018-01-24 2019-01-08 薬剤供給装置
CN201980009943.1A CN111655627A (zh) 2018-01-24 2019-01-08 药剂供给装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-009702 2018-01-24
JP2018009702 2018-01-24

Publications (1)

Publication Number Publication Date
WO2019146394A1 true WO2019146394A1 (ja) 2019-08-01

Family

ID=67395617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/000157 WO2019146394A1 (ja) 2018-01-24 2019-01-08 薬剤供給装置

Country Status (3)

Country Link
JP (1) JPWO2019146394A1 (zh)
CN (1) CN111655627A (zh)
WO (1) WO2019146394A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0322525U (zh) * 1989-07-11 1991-03-08
JP2000117263A (ja) * 1998-10-14 2000-04-25 Nippon Soda Co Ltd 固型薬剤連続自動溶出装置
JP2004008907A (ja) * 2002-06-06 2004-01-15 Mitsubishi Electric Corp 電解質供給装置
JP2015213891A (ja) * 2014-05-13 2015-12-03 パナソニックＩｐマネジメント株式会社 薬剤供給装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655874B1 (fr) * 1989-12-20 1992-03-13 Prolabo Sa Cellule de dissolution pour solides et appareil d'etude de la cinetique de dissolution la comportant.
US5427748A (en) * 1994-04-21 1995-06-27 Ppg Industries, Inc. Chemical feeder
CN105905957B (zh) * 2014-10-21 2018-12-28 谢文煌 Pcl自动计算加药剂量的污水处理设备加药装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0322525U (zh) * 1989-07-11 1991-03-08
JP2000117263A (ja) * 1998-10-14 2000-04-25 Nippon Soda Co Ltd 固型薬剤連続自動溶出装置
JP2004008907A (ja) * 2002-06-06 2004-01-15 Mitsubishi Electric Corp 電解質供給装置
JP2015213891A (ja) * 2014-05-13 2015-12-03 パナソニックＩｐマネジメント株式会社 薬剤供給装置

Also Published As

Publication number Publication date
JPWO2019146394A1 (ja) 2021-01-07
CN111655627A (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
JP2018527035A5 (zh)
US20050279768A1 (en) Method and apparatus for dispensing a filtered liquid
US20040144711A1 (en) Portable drinking device
TW201402187A (zh) 水處理筒
JP2018519013A5 (zh)
JP2013506547A (ja) 水処理カートリッジ
JP2013506607A (ja) 水処理装置のためのボトル
JP2012115747A (ja) 中空糸膜モジュールおよび中空糸膜モジュール濾過装置
JP2018518241A5 (zh)
WO2019146394A1 (ja) 薬剤供給装置
CN214270237U (zh) 水处理滤筒、限流单元、水容器和水分配器
JP5715631B2 (ja) ボトルドウォーターを製造するための水処理装置
KR20020067045A (ko) 음용 요소
WO2015199017A1 (ja) 吸着部材
JP2019537507A (ja) 液体処理デバイス、それを製造する方法、および液体処理システム
WO2019053937A1 (ja) 固形薬剤溶解装置
KR102213440B1 (ko) 탄산수 제조 장치
WO2020195368A1 (ja) 薬剤溶解装置
WO2019038787A1 (en) FILTER SET
WO2020262140A1 (ja) 薬剤供給装置
WO2001047818A1 (fr) Purificateur d'eau
JP7141350B2 (ja) 浄水カートリッジ
JP7227057B2 (ja) 浄水カートリッジの前処理方法
AU2003100299A4 (en) Drinking apparatus
WO2020022312A1 (ja) 薬剤溶解装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19744126

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019567955

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19744126

Country of ref document: EP

Kind code of ref document: A1